Immersive cardiac training tech gaining ground in high-stakes procedures

Tern plc

Fundamental XR is emerging as a key player in the shift toward immersive clinical training, offering a multimodal platform designed specifically for intracardiac interventions. Instead of relying on flat-screen visuals or isolated device simulations, this system merges real-world imaging modalities, including ultrasound, CT, fluoroscopy and 3D reconstructions, into a single virtual or mixed reality environment.

This matters because traditional training models are struggling to keep up with the demands of structural heart procedures. These interventions are becoming more intricate, with tighter tolerances and rising expectations around safety and efficiency. Platforms like Fundamental XR offer hospitals and manufacturers a tool to accelerate operator readiness, reduce avoidable errors, and improve procedural consistency, all of which are directly relevant to long-term value creation in this space.

What differentiates this model is its integration of full procedural context. Trainees don’t just learn isolated movements — they simulate the entire sequence of an intracardiac case, complete with real-time feedback from multimodal imaging. That creates a more realistic environment to develop the subtle spatial and tactile judgment needed for safe catheter navigation and device deployment. It also shortens the learning curve for new devices, which is increasingly important as manufacturers push for faster adoption cycles.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search